NDA 214621 · Sumitomo Pharma Am
Orgovyx
Relugolix · Oral · Gonadotropin Releasing Hormone Receptor Antagonist
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Nov 4, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Dec 18, 2020
Approved uses
2
Original approval plus efficacy supplements
Registered trials
72
24 Phase 3, 27 recruiting
FAERS reports
24,260
6,066 serious, 1,187 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 8, 2026.
ORGOVYX is indicated for the treatment of adult patients with advanced prostate cancer. ORGOVYX is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer ( 1 ).
Mechanism: Relugolix is a nonpeptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors, thereby, reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and consequently testosterone.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 18, 2024 Supplement 6 · Efficacy LetterLabel
- Dec 18, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
- ORGOVYX · RELUGOLIX 120MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Relugolix" as an intervention, any sponsor and status, largest first.
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialPivotal-lookingActive, not recruiting
NRG OncologyAcademic, hospital or other
NCT04513717 · 2,753 participants · Start Jan 21, 2021 · Primary completion Dec 31, 2033
Drug: Apalutamide; Bicalutamide and 8 more · For: Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
Sites: Fairbanks, Alaska; Gilbert, Arizona; Peoria, Arizona · 602 sites in all
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialPivotal-lookingActive, not recruiting
NRG OncologyAcademic, hospital or other
NCT05050084 · 2,050 participants (planned) · Start Dec 6, 2021 · Primary completion Nov 11, 2026
Drug: Bicalutamide; Buserelin and 8 more · For: Prostate Adenocarcinoma
Sites: Birmingham, Alabama; Gilbert, Arizona; Peoria, Arizona · 576 sites in all
- Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate CancerPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT07751133 · 1,500 participants (planned) · Start Aug 28, 2026 · Primary completion Aug 1, 2029
Drug: Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy · For: Prostate Cancer; mHSPC; mCRPC
Sites: Huddersfield, United Kingdom; Manchester, United Kingdom; Sutton, United Kingdom · 4 sites in all
- Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for PregnancyPivotal-lookingCompleted
Sumitomo Pharma Switzerland GmbHIndustry
NCT04756037 · 1,164 participants · Start Mar 18, 2021 · Primary completion Feb 25, 2025
Drug: Relugolix Combination Therapy · For: Contraception
Sites: Mobile, Alabama; Chandler, Arizona; Mesa, Arizona · 112 sites in all
- A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate CancerPivotal-lookingCompleted
Myovant Sciences GmbHIndustry
NCT03085095 · 1,134 participants · Start Apr 18, 2017 · Primary completion Oct 25, 2019
Drug: Relugolix; Leuprolide Acetate · For: Prostate Cancer
Sites: Tucson, Arizona; Orange, California; Denver, Colorado · 162 sites in all
- A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or EndometriosisPivotal-lookingRecruiting
Sumitomo Pharma Switzerland GmbHIndustry
NCT05862272 · 1,000 participants (planned) · Start Aug 14, 2023 · Primary completion Jul 2029
Drug: Relugolix Combination Tablet · For: Uterine Fibroids; Endometriosis
Sites: Mobile, Alabama; Chandler, Arizona; Mesa, Arizona · 120 sites in all
- Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET ImagingPivotal-lookingRecruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT04423211 · 804 participants (planned) · Start Oct 8, 2020 · Primary completion Dec 31, 2032
Drug: Apalutamide; Degarelix and 4 more · For: Biochemically Recurrent Prostate Carcinoma; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma and 1 more
Sites: Anchorage, Alaska; Fairbanks, Alaska; Phoenix, Arizona · 341 sites in all
- SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated PainPivotal-lookingCompleted
Myovant Sciences GmbHIndustry
NCT03654274 · 802 participants · Start May 22, 2018 · Primary completion Dec 16, 2021
Drug: Relugolix; Estradiol/norethindrone acetate · For: Endometriosis
Sites: Andalusia, Alabama; Scottsdale, Arizona; Tucson, Arizona · 169 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hot flush7,658
- fatigue5,907
- therapy interrupted3,381
- incorrect dose administered2,129
- asthenia1,977
- arthralgia1,592
- diarrhoea1,554
- dizziness1,344
- product dose omission issue1,338
- constipation1,049
- death1,005
- weight increased894
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 472 |
| 2022 | 2,334 |
| 2023 | 2,979 |
| 2024 | 5,774 |
| 2025 | 10,315 |
| 2026 | 2,376 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Orgovyx (Relugolix)
2024 spending
$484M
Beneficiaries
28,521
180,761 claims
Per beneficiary
$16,981
$87.04 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $51,999,804 |
| 2022 | $165,989,470 |
| 2023 | $276,597,252 |
| 2024 | $484,308,516 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Shore ND, Saad F, Cookson MS, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Comparative Study
- Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.
Al-Hendy A, Lukes AS, Poindexter AN, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Multicenter Study
- The Effect of Hormonal Treatment on Ovarian Endometriomas: A Systematic Review and Meta-Analysis.
Thiel PS, Donders F, Kobylianskii A, et al. · J Minim Invasive Gynecol 2024 · Meta-Analysis, Systematic Review
- LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids.
Al-Hendy A, Venturella R, Arjona Ferreira JC, et al. · Am J Obstet Gynecol 2023 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Efficacy of GnRH antagonists in the treatment of uterine fibroids: a meta-analysis.
Sánchez Martín MJ, Huerga López C, Cristóbal García I, et al. · Arch Gynecol Obstet 2025 · Meta-Analysis, Review
- Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
Tutrone R, Saad F, George DJ, et al. · Eur Urol Oncol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Sumitomo Pharma Am
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.